PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMethamphetamine
Methamphetamine
Desoxyn, Methamphetamine (methamphetamine) is a small molecule pharmaceutical. Methamphetamine was first approved as Desoxyn on 1982-01-01. It is used to treat attention deficit disorder with hyperactivity, narcolepsy, and obesity in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
mental disordersD001523
Trade Name
FDA
EMA
Desoxyn, Methamphetamine (discontinued: Desoxyn, Methampex, Methamphetamine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methamphetamine hydrochloride
Tradename
Company
Number
Date
Products
DESOXYNKey TherapeuticsN-005378 RX1982-01-01
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
methamphetamine hydrochlorideANDA2024-12-10
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06B: Psychostimulants, agents used for adhd and nootropics
— N06BA: Centrally acting sympathomimetics
— N06BA03: Metamfetamine
HCPCS
No data
Clinical
Clinical Trials
381 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Substance-related disordersD019966EFO_0003890F131419332560
Hiv infectionsD015658EFO_0000764B2018—21020
DepressionD003863—F33.91—1349
Mental disordersD001523EFO_0000677F91.91——348
Acquired immunodeficiency syndromeD000163EFO_0000765B2011—146
Cognitive dysfunctionD060825—G31.84———145
Depressive disorderD003866EFO_1002014F32.A———123
Psychotic disordersD011618—F20.81———213
Problem behaviorD000066553—————123
RecurrenceD012008———1—113
Show 17 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnxietyD001007EFO_0005230F41.1—11—24
Drug overdoseD062787———21—13
Rheumatoid arthritisD001172EFO_0000685M06.9——1——1
ArthritisD001168EFO_0005856M05-M14——1——1
Substance withdrawal syndromeD013375EFO_0005800——11——1
Critical illnessD016638————1——1
Acute kidney injuryD058186—N17——1——1
Pain managementD059408————1——1
Periodontal diseasesD010510—K05.6—11——1
HypersensitivityD006967EFO_0003785T78.40—11——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Amphetamine-related disordersD019969EFO_0004701F151113——1436
Addictive behaviorD016739EFO_0004347—25——916
HivD006678—O98.724——812
StrokeD020521EFO_0000712I63.921——57
Opioid-related disordersD009293EFO_0005611F11—1——56
Sexually transmitted diseasesD012749—A50-A6412——14
AlcoholismD000437EFO_0003829F10.1—2——13
Hiv seropositivityD006679———1——12
ObesityD009765EFO_0001073E66.9—1——12
Alcohol drinkingD000428EFO_0004329——1——12
Show 11 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dental cariesD003731EFO_0003819K022———1618
Healthy volunteers/patients———4———37
Root cariesD017213EFO_1001163—1———23
Dental restoration failureD019232——1———12
AffectD000339——1———12
Colorectal neoplasmsD015179——1————1
Second primary neoplasmsD016609——1————1
Liver neoplasmsD008113EFO_1001513C22.01————1
Colonic neoplasmsD003110—C181————1
Rectal neoplasmsD012004——1————1
Show 9 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FatigueD005221—R53.83————44
Sleep wake disordersD012893—G47————44
Cocaine-related disordersD019970—F14————44
Bipolar disorderD001714EFO_0000289F30.9————44
Parkinson diseaseD010300EFO_0002508G20————44
ParasomniasD020447—G47.5————33
Medication adherenceD055118EFO_0006344—————33
AgingD000375GO_0007568R41.81————33
AmblyopiaD000550—H53.00————33
Spinal cord injuriesD013119EFO_1001919—————33
Show 116 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMethamphetamine
INNmetamfetamine
Description
Methamphetamine[note 1] (contracted from N-methylamphetamine) is a potent central nervous system (CNS) stimulant that is mainly used as a recreational drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder and obesity. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine.[note 2] Methamphetamine properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms, but the hydrochloride salt, commonly called crystal meth, is widely used. Methamphetamine is rarely prescribed over concerns involving human neurotoxicity and potential for recreational use as an aphrodisiac and euphoriant, among other concerns, as well as the availability of safer substitute drugs with comparable treatment efficacy such as Adderall and Vyvanse. Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN[C@@H](C)Cc1ccccc1
Identifiers
PDB—
CAS-ID537-46-2
RxCUI—
ChEMBL IDCHEMBL1201201
ChEBI ID6809
PubChem CID1206
DrugBankDB01577
UNII ID44RAL3456C (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Methamphetamine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 44,248 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
10,204 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use